Blood advances
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia.
Saurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, Damien Roos-Weil, Dirk R Larson, Colin L Colby, Eric Durot, Efstathios Kastritis, Encarl Uppal, Oliver Tomkins, Pierre Morel, Patrizia Mondello, Lydia Montes, Jonas Paludo, Sikander Ailawadhi
Published: 202610.1182/bloodadvances.2025017751
Abstract
Waldenström macroglobulinemia (WM) is characterized by recurrent MYD88 and CXCR4 mutations, whose prognostic value in chemoimmunotherapy-treated patients remains unclear. Moreover, the typically prolonged progression-free survival (PFS) correlates in…
Preview only. Read the full abstract at the source